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RESEARCH PAPER
Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase
Dres Damgaarda,b, Mads Emil Bjørna,c, Peter Østrup Jensena,d and Claus Henrik Nielsena,b
aInstitute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen,
Denmark; bSection for Periodontology, Microbiology and Community Dentistry, Department of Odontology, Faculty of Health and Medical
Sciences, University of Copenhagen, Copenhagen, Denmark; cDepartment of Haematology, Roskilde Hospital, Roskilde, Denmark; dDepartment of
Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
ABSTRACT
Protein citrullination catalysed by peptidylarginine deiminase (PAD) may play an important pathogenic
role in several chronic inflammatory diseases and malignancies. PAD2, PAD4, and citrullinated proteins are
found in the synovium of rheumatoid arthritis patients. PAD activity is dependent on calcium and reducing
conditions. However, reactive oxygen species (ROS) have been shown to induce citrullination of histones
in granulocytes. Here we examine the ability of H2O2 and leukocyte-derived ROS to regulate PAD activity
using citrullination of fibrinogen as read-out. H2O2 at concentrations above 40mM inhibited the catalytic
activity of PAD2 and PAD4 in a dose-dependent manner. PMA-stimulated leukocytes citrullinated fibrino-
gen and this citrullination was markedly enhanced when ROS formation was inhibited by the NADPH oxi-
dase inhibitor diphenyleneiodonium (DPI). In contrast, PAD released from stimulated leukocytes was
unaffected by exogenously added H2O2 at concentrations up to 1000mM. The role of ROS in regulating
PAD activity may play an important part in preventing hypercitrullination of proteins.
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Citrullination, i.e. conversion of peptidyl-arginine into peptidyl-cit-
rulline, is a post-translational protein modification catalysed by
peptidylarginine deiminase (PAD) in a calcium-dependent man-
ner1. Five isoforms of PAD exists2, of which PAD2 and/or PAD4 are
thought to play important pathophysiological roles in chronic
inflammatory diseases such as RA3, multiple sclerosis and type 1
diabetes4–6, as well as in certain forms of cancer7.
In addition to calcium, the catalytic activity of PAD requires
reducing conditions8. These are usually obtained in vitro using the
non-physiological reducing agent dithiothreitol (DTT). We demon-
strated recently that reduced glutathione (GSH), at low millimolar
range corresponding to those found intracellularly9,10, can substi-
tute for DTT as PAD-activating reducing agent11. Moreover, we
found that PAD released from phorbol 12-myristate 13-acetate
(PMA)-stimulated leukocytes was capable of citrullinating fibrino-
gen in the vicinity, with granulocytes being the predominant
source of active PAD11. However, PAD contained in cell superna-
tants was inactive, which lead us to hypothesize that it was rapidly
oxidized.
Activated neutrophils produce superoxide radical (O·2
) cata-
lysed by the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase 2 (NOX2)12,13. Consequently, other reactive oxy-
gen species (ROS) are formed, including hydrogen peroxide
(H2O2), hydroxyl radicals, and hypochlorous acid
14,15. ROS can be
released from neutrophils in response to strong stimuli such as
PMA, or the physiological secretagogues, including immune com-
plexes, C5a, N-formylated peptides, leukotrienes, platelet-activating
factor, and arachidonic acid16–22. Intracellular ROS may promote
intracellular histone H3 citrullination23,24 and NETosis23,25, which
has led to the suggestion that ROS may activate PAD4 down-
stream26. However, such studies have generally not concerned
extracellular proteins, which account for a large part of citrulli-
nated proteins in the synovium of RA patients27,28.
Here, we examine the direct effect of H2O2 on the activity of
recombinant human PAD2 and PAD4, and on the extracellular cit-
rullination mediated by PAD released from PMA-stimulated leuko-
cytes. Moreover, the role of NOX2 in regulation of extracellular
PAD activity is examined.
Experimental procedures
Cells
Blood samples were drawn into 9ml lithium-heparin tubes (BD
Bioscience, Brøndby, Denmark) from healthy donors attending the
Blood Bank at Copenhagen University Hospital, Rigshospitalet,
Denmark. The National Ethical Committee of Denmark waived the
need for ethical approval for this study due to the anonymity of
the donors included. Pooled serum from blood group AB-positive
donors, henceforward referred to as “AB serum”, was purchased
from Sigma-Aldrich (St Louis, MO). Leukocytes were isolated after
lysis of erythrocytes by incubation with ammonium chloride buffer
(In Vitro As, Fredensborg, Denmark) for 7min in the dark. Upon
lysis, cell were centrifuged at 300 g, at room temperature for 5min
and washed twice in RPMI 1640, 25mM Hepes containing 0.42mM
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calcium nitrate, L-Glutamine and Gentamicin (In Vitro As,
Fredensborg, Denmark).
Reagents
Recombinant human PAD2 (rhPAD2) and rhPAD4 were produced
and purified as described previously29. GSH, diphenyleneiodonium
(DPI), PMA, fetal calf serum (FCS), and H2O2 were purchased from
Sigma-Aldrich. Dihydrorhodamine-123 (DHR-123) and near-infra-
red (NIR) were purchased from Molecular Probes (Life
Technologies Europe BV, Naerum, Denmark). Monoclonal mouse
anti-citrullinated fibrinogen antibody (clone 20B2) was purchased
from ModiQuest (Oss, Netherlands). Allophycocyanin (APC)-conju-
gated anti-CD15 antibody was purchased from BD Bioscience
(Albertslund, Denmark).
Assay for PAD activity
As described11, Maxisorp plates (Nunc, Roskilde, Denmark) were
coated overnight at 4 C with 1mg/ml fibrinogen (Calbiochem,
Darmstadt, Germany). Wells were washed thrice and blocked in Tris-
buffered saline (TBS) buffer containing 0.05% Tween-20, pH 7.4.
Hereafter, the wells were incubated for 3 h at room temperature (RT)
with PAD-containing samples with or without GSH, H2O2, and EDTA,
as stated in figure legends. Purified leukocytes were applied in RPMI
1640 containing 5% AB serum and, when relevant, 15nM PMA,
25mM DPI, which inhibits NOX2 and other flavoenzymes by interact-
ing with the flavin part30, or H2O2 at various concentrations. After
three washes in washing buffer (PBS, 0.05% Tween-20, pH 7.4),
mouse anti-citrullinated fibrinogen antibody (0.5mg/ml) and hereafter
horse radish peroxidase-conjugated polyclonal rabbit-anti mouse
immunoglobulin antibodies (P0260, Dako, Glostrup, Denmark) were
added and developed as described11. Optical density (OD) was meas-
ured at 490–650nm using the SPECTROstar nano Microplate Reader
(BMG Labtech, Ortenberg, Germany). Data were processed using
MARS software (BMG Labtech).
Measurement of PAD2 concentration
PAD2 was measured using an in-house luminex based sandwich
immunoassay using two specific anti-PAD2 antibodies previously
used in an ELISA31. The lower limit of detection of PAD2 was
100 pg/ml using rhPAD2 as calibrator. Cell supernatants were
diluted 1:1 with PBS containing 0.05% Tween-20, pH 7.4.
Flow cytometric assessment of H2O2 formation by granulocytes
Isolated blood leukocytes from 9ml blood were resuspended in
9ml RPMI containing 10% AB serum. DHR-123 was added to all the
tubes to a final concentration of 1.5 mM. Half of the samples
received 25mM DPI. Each group of samples were incubated with
H2O2, at various concentrations, or were stimulated with 30 nM
PMA or left unstimulated for 60min at 37 C, 5% CO2. After wash in
RPMI, the cells were stained incubated for 40min at RT with APC-
conjugated anti-CD15 antibody for identification of live neutrophils,
and LIVE/DEADVR Fixable Near-IR (NIR) Dead Cell Stain (Molecular
Probes, Eugene, OR) in order to discriminate between live and dead
cells. Cells were subsequently acquired on a FACS-CANTO-II Flow-
cytometer (BD Bioscience) and analysed using Flow-Jo software
(version 10, Ashland, OR). The amount of H2O2 in the granulocytes
was expressed as the median fluorescence intensity within the FITC-
channel (FL-1) of live (NIR-negative) granulocytes, defined on the
basis of morphological forward light scatter (FSC)/side light scatter
(SSC) gate and positivity for CD15-expression.
Statistics
Wilcoxon matched-pairs signed rank test was applied to compare
PAD activity or PAD2 release in the presence and absence of DPI.
To this end, the GraphPad Prism 7.02 software (GraphPad,
San Diego, CA) was employed. Two-tailed p values < .05 were con-
sidered significant.
Results
Reactive oxygen species inhibit PAD activity
Using human fibrinogen coated on microtiter plates as substrate,
we measured the catalytic activity of rhPAD2 or rhPAD4 in the pres-
ence of a reaction buffer containing 15mM GSH and 5mM calcium,
previously shown to be optimal for PADs to be enzymatically
active11. At concentrations above 40mM, exogenously added H2O2
lowered the catalytic activity of rhPAD2 and rhPAD4 in a dose-
dependent manner, which did not differ between the two PAD iso-
forms (Figure 1A) Half-maximal PAD activity was observed at
130 mM H2O2, and virtually no activity was observed at concentra-
tions above 600 mM. At neither of concentrations used did H2O2
cause changes in fibrinogen affecting the binding of the probing
antibody or potentially influential changes in pH32 (data not shown).
Figure 1. Effect of ROS on PAD activity. (A) Microtiter wells were coated with human fibrinogen and incubated for 3 h at room temperature with rhPAD2 (300 ng/ml)
or rhPAD4 (3000 ng/ml) in 100mM Tris-HCl including 15mM reduced glutathione (GSH) and 5mM CaCl2. (B) Supernatants from unstimulated leukocytes or leukocytes
stimulated with PMA for 30min. were added 1:1 to wells containing rhPAD2 (300 ng/ml) in 100mM Tris-HCl including various concentrations of glutathione (GSH) and
5mM CaCl2. In both experiments, mAb 20B2 recognizing a citrullinated epitope on fibrinogen was used as probe. PAD activity is shown as per cent of maximal activity
for each isoform, expressed as mean and range of duplicate measurements.































To examine if ROS are secreted by leukocytes in sufficient
amounts to inhibit PAD activity, we added supernatants from
PMA-stimulated or unstimulated leukocytes to rhPAD2 in reaction
buffer (Figure 1(B)). More reducing agent (25mM GSH) was
required to obtain maximal rhPAD2 activity in the presence of
supernatants from stimulated leukocytes than in the presence of
supernatants from unstimulated leukocytes (15mM GSH), sug-
gesting that ROS secreted by activated leukocytes inhibit PAD.
Inhibition of NOX2 enhances the activity of PAD released from
activated leukocytes
Granulocytes are the main source of enzymatically active PAD in
the vicinity of PMA-stimulated leukocytes11. We therefore meas-
ured H2O2 production by granulocytes using DHR-123 as probe.
As expected, PMA induced extensive production of H2O2 by gran-
ulocytes, which was almost abrogated by inhibition of NOX2
(Figure 2(A) and flow cytometry histograms in Supplementary
Figure S1).
The extracellular PAD activity from PMA-stimulated leukocytes
was increased after DPI-mediated inhibition of the NOX2, indicat-
ing that ROS formation inactivates PAD and thereby extracellular
citrullination (Figure 2(B)). The observed increase in PAD activity
was not a result of increased PAD release, since a decrease was
observed in the levels of extracellular PAD2 (which accounts for
the major activity in the assay employed33) (Figure 2(C)). In agree-
ment with previous findings34, the proportion of live granulocytes
increased from an average of 36% to 68% after inclusion of DPI
(data not shown).
Only supraphysiological levels of ROS inhibit citrullination by
PAD released from leukocytes
Exogenously added H2O2 oxidized DHR-123 in a dose-dependent
manner, as expected in view of its ability to diffuse over cell mem-
branes35 (Figure 3(A) and flow cytometry histograms in
Supplementary Figure S1). The oxidation observed in the presence
of highest concentration of H2O2 tested, 10,000 mM, exceeded that
Figure 2. Influence of oxidation on PAD activity and amount of PAD2 released from activated leukocytes. (A) Bars show the median fluorescence intensity (MFI) of
rhodamine-123 by CD15-positive, live (NIR-negative) granulocytes from two independent experiments. Leukocytes from two donors resuspended in RPMI medium con-
taining 5% normal human serum were left unstimulated or were stimulated with PMA in the absence or presence of the NADPH oxidase inhibitor DPI. (B) Microtiter
wells were coated with human fibrinogen and incubated for 3 h with PMA-stimulated leukocytes in the absence or presence of DPI, and mAb 20B2 was used as probe
for citrullination. The average of duplicate measurements for each of eight donors is shown. (C) The corresponding concentration of PAD2 in the supernatants is
shown.
Figure 3. PAD activity and PAD2 release in stimulated leukocytes in the presence of H2O2. (A) Leukocytes were exposed to various concentration of H2O2 in the
absence and presence of DPI. Histograms show the median fluorescence intensity (MFI) of rhodamine-123 in CD15-positive, live (NIR-negative) granulocytes.
(B) Microtiter wells coated with human fibrinogen were incubated for 3 h at room temperature with unstimulated or PMA-stimulated leukocytes resuspended in RPMI
medium containing 5% normal human serum with or without DPI and various concentrations of H2O2. Citrullination of fibrinogen was measured using mAb 20B2 as
detecting antibody. Bars and error bars show mean and SEM of experiments involving four healthy donors. (C) PAD2 concentrations in the corresponding cell superna-
tants are shown.































observed upon stimulation with PMA (Figure 2(A)). To examine
the influence of ROS on the activity of PAD released from leuko-
cytes, we added H2O2 to unstimulated and PMA-stimulated leuko-
cytes (Figure 3(B)). At a range of 10–1000 mM, exogenously added
H2O2 had little effect on the extracellular citrullination.
Endogenously produced ROS, on the other hand, mediated a
much more efficient reduction in PAD activity, as demonstrated
by a markedly enhanced citrullination in the presence of DPI
(Figures 2(B) and 3(B)). At a concentration of 10,000 mM, however,
H2O2 inhibited citrullination both in the presence and absence of
DPI. This was not a result of a reduction of PAD release, since
PAD2 release was slightly increased under these conditions
(Figure 3(C)).
Discussion
In view of previous findings that reduction by GSH is required for
PAD activity11, we hypothesized that ROS would have an opposing
effect. At concentrations above 40 mM, H2O2 directly inactivates
the enzymatic activity of rhPAD2 and rhPAD4 reduced by GSH at
a concentration of 15mM, which can be achieved intracellu-
larly9,10. Concordantly, supernatants from PMA-stimulated leuko-
cytes inhibited rhPAD2-mediated citrullination observed at this
GSH concentration, suggesting that the PMA-stimulated leukocytes
have released ROS into the supernatant. Presumably neutrophils
were the main contributors to the secretion of ROS16–22. In fact,
release of H2O2 by PMA-stimulated human neutrophils has been
confirmed by various methods36–38.
To avoid stimulation of granulocytes by handling and to mimic
in vivo conditions, e.g. in an inflamed joint, we used unseparated
leukocyte populations in this study. In keeping with the inhibitory
effect of H2O2 on rhPAD, the citrullination catalysed by PAD
released from activated leukocytes was inhibited by ROS produced
by the PMA-stimulated leukocytes, as demonstrated by a signifi-
cant increase in PAD activity after inhibition of the NOX2 with DPI.
This increase occurred, even though DPI lowered PAD2 release,
presumably by lowering cell death and thereby leakage of PAD2.
Granulocytes are the predominant source of extracellular PAD
upon stimulation with PMA11, and also the prime site for intracel-
lular hypercitrullination39. The NOX2 generates ROS that are deliv-
ered either into the extracellular space or to intracellular
compartments (reviewed in Ref. [40]), and it cannot be determined
whether PAD was oxidized intracellularly, prior to release, or
extracellularly in the present study. Since extracellular, matrix-
bound fibrinogen was used as probe for citrullination, the
increased citrullination observed following incubation of leuko-
cytes with DPI suggests that NOX2-mediated oxidation regulates
extracellular citrullination, if not also intracellular citrullination.
At a supraphysiological concentration of 10,000 mM, exogen-
ously added H2O2 completely abrogated activity of PAD released
from leukocytes. This is in line with the observation by Neeli et al.
that addition of 10,000 mM H2O2 to neutrophils prevents citrullina-
tion of histone H324. Concentrations of 10–1000 mM H2O2, on the
other hand, promoted intracellular histone citrullination in their
study24, but showed no effect on extracellular citrullination in the
present study. Extracellular concentrations of H2O2 above 1mM
are not considered physiological achievable41,42, but we cannot
rule out that H2O2 concentrations transiently exceed this level,
which may inhibit extracellular PAD in vivo. It can be speculated
that PAD is relatively well protected from oxidation by H2O2 within
the cell, e.g. by co-localizing with GSH and catalases. In fact,
intense activity of the myeloperoxidase prevents accumulation of
H2O2 above 30 mM in the phagosome in spite of superoxide (O2
1)
being produced at levels exceeding 1 M43.
Most studies find that PMA and H2O2 promote citrullination of
histone H324,39,23, but in some studies PMA fails to do so44,45. To
the best of our knowledge, no other proteins than histones have
been shown to be citrullinated by PAD in combination with H2O2
or other ROS. PMA-induced histone H3 citrullination can be inhib-
ited by DPI39, suggesting that citrullination of histone H3 is,
indeed, ROS dependent. Calcium ionophores are inducers of intra-
cellular hypercitrullination45, but this citrullination can be inhibited
by PMA44, presumably by the ROS that PMA induces. It can be
speculated that the previously reported enhancing effect of ROS
on histone citrullination is secondary to ROS’ facilitation of calcium
transport, e.g. into the nucleus46,47.
Several observations indicate that RA patients have a dysregu-
lated redox balance, e.g. increased levels of antioxidants, limited
access to oxygen within the joints, and granulocytes with
impaired ability to produce ROS: RA patients have increased
glutathione reductase activity in synovial fluid (SF), compared to
SF from reactive arthritis and osteoarthritis patients48, and the
antioxidant thioredoxin has been reported to be increased 5-fold
in SF from RA patients compared to SF from patients with osteo-
arthritis49. In accordance, SF from RA patients has higher anti-oxi-
dative capacity than SF from osteoarthritis patients50, and anti-
CCP positive patients’ SF has higher antioxidative capacity than
that of anti-CCP negative patients51. As molecular oxygen (O2) is
prerequisite for ROS production by leukocytes52,53, the low con-
tent of O2 in synovial joint fluids and tissue in RA
54,55 presumably
is reflected by sparse accumulation of H2O2. In fact, the levels of
O2 in the joints of patients with RA are usually lower than the
estimated Km of the NOX2 at 30mM O2
53, and ROS production by
phagocytes isolated from RA patients is reduced56,57. Thus, accu-
mulation of H2O2 at levels capable of inhibiting PADs may not be
achieved, which may cause the excessive protein citrullination in
the joints of RA27,58.
Conclusion
In conclusion, we demonstrate that the catalytic activity of PAD2
and PAD4 is inhibited by H2O2, and that extracellular citrullination
is inhibited by ROS generated by NOX2 in activated leukocytes.
This confirms our previous suggestion11 that the catalytic activity
of PAD is enhanced in reducing conditions in vivo, and thereby is
regulated by the redox balance.
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